Market Research Logo

Age-Related Macular Degeneration Pipeline Highlights – 2017 Update

Age-Related Macular Degeneration Pipeline Highlights – 2017 Update

The latest report from Fore Pharma, Age-Related Macular Degeneration Pipeline Highlights – 2017 Update, provides most up-to-date information on key pipeline products in the global Age-Related Macular Degeneration market. It covers emerging therapies for Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Age-Related Macular Degeneration pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Age-Related Macular Degeneration pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Age-Related Macular Degeneration pipeline products by the company.

Short-term Launch Highlights:
Find out which Age-Related Macular Degeneration pipeline products will be launched in the US and Ex-US till 2020.

SUMMARY:

  • Age-Related Macular Degeneration phase 3 clinical trial pipeline products
  • Age-Related Macular Degeneration phase 2 clinical trial pipeline products
  • Age-Related Macular Degeneration phase 1 clinical trial pipeline products
  • Age-Related Macular Degeneration preclinical research pipeline products
  • Age-Related Macular Degeneration discovery stage pipeline products
  • Age-Related Macular Degeneration pipeline products short-term launch highlights


1. Age-Related Macular Degeneration Pipeline by Stages
2. Age-Related Macular Degeneration Pipeline by Drug Class
3. Age-Related Macular Degeneration Pipeline by Company
4. Age-Related Macular Degeneration Phase 3 Clinical Trial Insights
5. Age-Related Macular Degeneration Phase 2 Clinical Trial Insights
6. Age-Related Macular Degeneration Phase 1 Clinical Trial Insights
7. Age-Related Macular Degeneration Preclinical Research Insights
8. Age-Related Macular Degeneration Discovery Stage Insights
9. Appendix
10. Research Methodology
LIST OF TABLES
Table 1: Age-Related Macular Degeneration Phase 3 Clinical Trials, 2017
Table 2: Age-Related Macular Degeneration Phase 2 Clinical Trials, 2017
Table 3: Age-Related Macular Degeneration Phase 1 Clinical Trials, 2017
Table 4: Age-Related Macular Degeneration Preclinical Research, 2017
Table 5: Age-Related Macular Degeneration Discovery Stage, 2017
LIST OF FIGURES
Figure 1: Age-Related Macular Degeneration Pipeline Molecules by Clinical Trials Stage, 2017
Figure 2: Age-Related Macular Degeneration Pipeline Molecules by Drug Class, 2017
Figure 3: Age-Related Macular Degeneration Pipeline Molecules by Company, 2017
Figure 4: Age-Related Macular Degeneration Phase 3 Clinical Trial Highlights, 2017
Figure 5: Age-Related Macular Degeneration Phase 2 Clinical Trial Highlights, 2017
Figure 6: Age-Related Macular Degeneration Phase 1 Clinical Trial Highlights, 2017
Figure 7: Age-Related Macular Degeneration Preclinical Research Highlights, 2017
Figure 8: Age-Related Macular Degeneration Discovery Stage Highlights, 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report